Research has demonstrated that patients with melanoma may develop acquired resistance to anti-cancer therapy due to the activation of the PI3K signaling pathway, either as a result of PTEN loss or PIK3CA mutations (Tran et al., 2021). The gene discussed is PTEN; the disease is melanoma.